TSS
OREX

Two Sigma Securities’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Two Sigma Securities’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-22,934
Closed -$40K – 1275
2016
Q4 		$40K Buy
22,934
+12,456
+119% +$29.3K 0.01% 615
2016
Q3 		$35K Buy
+10,478
New +$39.6K 0.01% 580

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

Two Sigma Securities's OREX Position: Q1 2017 in Review

Two Sigma Securities sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2017, closing a stake of 22,934 shares — an estimated $40K sold.

Two Sigma Securities first reported a position in OREX in Q3 2016 and held it in 2 quarters. The position peaked at $40K in Q4 2016. 52 funds tracked by Wall St. Rank hold OREX as of Q1 2017.

  • Two Sigma Securities reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Two Sigma Securities sold 22,934 Orexigen Therapeutics, Inc. shares in Q1 2017, an estimated $40K.
  • Two Sigma Securities first reported a position in Orexigen Therapeutics, Inc. in Q3 2016 and held it in 2 quarters.
  • Two Sigma Securities's Orexigen Therapeutics, Inc. position peaked at $40K in Q4 2016.
  • 52 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2017.

Based on Two Sigma Securities's 13F filing for Q1 2017, filed 15 May 2017.